I would like to know how many of those critical of PPHM's phase II 2nd or 1st line NSCLC trials have themselves designed what they consider an appropriately designed trial in an identical or substantially identical situation.
Do any of you know personally Dr. Bruce Chabner, of Harvard I believe, and his area of expertise?
Market Data 
Markets 
AI
